# Nestlé Health Science

> Nestlé Health Science is a VC fund backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Vevey, Switzerland
- Total investments: 7
- Last investment: Jan 2024
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nestle-health-science
- X (Twitter): https://www.twitter.com//
- Website: http://www.nestlehealthscience.com

Nestlé Health Science is a VC fund in Vevey focused on Health Care and Biotechnology. Nestlé Health Science began operations on January 1, 2011. As a wholly-owned subsidiary of Nestlé, with global headquarters in Vevey, Switzerland, Nestlé Health Science has a distinct role to play in the Nestlé’s transformation into the world’s recognised leader in Nutrition, Health and Wellness. At Nestlé Health Science, their specific quest is tobecome the global leader in science-based personalised nutritional solutions.Nestlé Health Science has been established to pioneer science-based nutritional solutions in order to deliver improved personalised healthcare for medical conditions. In the longer term, the company aims to use nutritional solutions to change the healthcare paradigm and deliver affordable and effective health benefits which are also safe and sustainable. The company intends to use Nestlé's existing HealthCare Nutrition business to build a leading health science nutrition organisation within two years. It aims to develop a product portfolio and pipeline within five years and establish market leadership, meeting its vision, within a decade from start-up. The company has access to external scientific and technological know-how through Nestlés innovation network as well as a number of venture capital funds in which the group has interests.

## Contacts

5 contacts available for Nestlé Health Science. Shizune tracks 7 team members at Nestlé Health Science. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nestl-health-science?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 71% |
| Biotechnology | 3 | 43% |
| Beauty | 1 | 14% |
| Medical | 1 | 14% |
| Hospital | 1 | 14% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 2 | 29% |
| Series E | 1 | 14% |
| Debt Financing | 1 | 14% |
| Private Equity | 1 | 14% |
| Post-IPO Equity | 1 | 14% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 29% |
| China | 1 | 14% |
| France | 1 | 14% |
| Switzerland | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Peter Letmathe | Chairman | 3 | https://shizune.co/investors/profile/peter-brabeck-letmathe |
| Emmanuel Baetge | Director | 0 | — |
| Greg Behar | President & CEO | 0 | — |
| Gunnart Weikert | Director | 0 | — |
| Hermann Wirz | Director | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Timeline | Amazentis is a life science company that conducts research on medication and nutrition.The company focuses on the development of products that meet the health requirements of the aging population. Their products target the reversal of age-related muscle decline by improving the activity of mitochondria.Amazentis was founded in 2007 by PierreLandolt and Patrick Aebischer and is based in Lausanne. | $65M | Series D | Jan 16, 2024 |  |
| Ruipeng Pet Healthcare | Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator, which covers pet healthcare, foster care, bathing, SPA, beauty, food, entertainment and leisure services. |  | Private Equity | Dec 23, 2022 |  |
| ProciseDx | ProciseDx offers point-of-care testing that yields precise, high-quality results, thereby empowering both physicians and patients. It allows patients to leave appointments with answers rather than simply another appointment. Its point-of-care diagnostic solutions allow patients and physicians to make more informed decisions. | $13M | Convertible Note | Jul 13, 2021 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $51.9M | Series E | Jun 25, 2020 |  |
| Aimmune Therapeutics | Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patientsto food allergens using characterized biologic products, defined treatment protocols, and support services. | $200M | Post-IPO Equity | Feb 05, 2020 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $43.9M | Debt Financing | Jan 04, 2018 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $35.1M | Series D | Jan 01, 2017 |  |

7 of 7 investments shown.

## Co-investors
- Health for Life Capital fund — VC Fund, 3 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 3 deals together
- [Principia SGR](https://shizune.co/investors/profile/quantica-sgr) — VC Fund, 3 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 3 deals together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 2 deals together
- [Lundbeckfonden Ventures](https://shizune.co/investors/profile/lundbeckfond-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Nestlé Health Science invest in?

Nestlé Health Science invests primarily in Health Care, Biotechnology and Beauty startups, most often at Series D and Series E stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Nestlé Health Science?

Public channels for Nestlé Health Science include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Nestlé Health Science?

The team at Nestlé Health Science includes Peter Letmathe (Chairman), Emmanuel Baetge (Director) and Greg Behar (President & CEO), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co